We describe and assess the quality of the assimilated ozone product from the Modern-Era Retrospective Analysis for Research and Applications, Version 2 (MERRA-2) produced at NASA's Global Modeling and Assimilation Office (GMAO) spanning the time period from 1980 to present. MERRA-2 assimilates partial column ozone retrievals from a series of Solar Backscatter Ultraviolet (SBUV) radiometers on NASA and NOAA spacecraft between January 1980 and September 2004; starting in October 2004 retrieved ozone profiles from the Microwave Limb Sounder (MLS) and total column ozone from the Ozone Monitoring Instrument on NASA's EOS Aura satellite are assimilated. We compare the MERRA-2 ozone with independent satellite and ozonesonde data focusing on the representation of the spatial and temporal variability of stratospheric and upper tropospheric ozone and on implications of the change in the observing system from SBUV to EOS Aura. The comparisons show agreement within 10 % (standard deviation of the difference) between MERRA-2 profiles and independent satellite data in most of the stratosphere. The agreement improves after 2004 when EOS Aura data are assimilated. The standard deviation of the differences between the lower stratospheric and upper tropospheric MERRA-2 ozone and ozonesondes is 11.2 % and 24.5 %, respectively, with correlations of 0.8 and above, indicative of a realistic representation of the near-tropopause ozone variability in MERRA-2. The agreement improves significantly in the EOS Aura period, however MERRA-2 is biased low in the upper troposphere with respect to the ozonesondes. Caution is recommended when using MERRA-2 ozone for decadal changes and trend studies.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5842360 | PMC |
http://dx.doi.org/10.1175/JCLI-D-16-0699.1 | DOI Listing |
Mult Scler Relat Disord
December 2024
Department of Clinical Medicine, University of Bergen, Bergen, Norway; Neuro-SysMed, Department of Neurology, Haukeland University Hospital, Bergen, Norway. Electronic address:
Background: Alemtuzumab is approved in the European Union for treating highly active relapsing-remitting multiple sclerosis (RRMS). Patient-reported outcomes measure the treatment impact on quality of life (QoL), including fatigue, a common symptom in multiple sclerosis (MS). Chronic diseases like MS also affect the patient's caregiver.
View Article and Find Full Text PDFCureus
September 2024
Neurosurgery, Hôtel-Dieu de France, Beirut, LBN.
Objective This study aims to develop a quantifiable model for evaluating the outcomes of vagus nerve stimulation (VNS) in patients with multifocal refractory epilepsy, particularly focusing on those who have undergone multiple surgeries. By adopting a patient-centered approach, the study seeks to provide a robust framework for assessing VNS efficacy across various patient demographics, including both adult and pediatric patients, and those with impaired cognitive and communicative abilities. Methods We conducted a retrospective analysis of 49 patients with multifocal refractory epilepsy who underwent at least one VNS surgery.
View Article and Find Full Text PDFJ Emerg Trauma Shock
February 2024
Department of Surgery, Trauma Surgery Section, Hamad General Hospital, Doha, Qatar.
Sci Rep
May 2023
Department of Biomedical Sciences, Faculty of Medicine and Health Sciences, An-Najah National University, Nablus, Palestine.
The rising incidence of cancer and the lack of effective therapeutic interventions for many neurological illnesses like Alzheimer's and epilepsy has prompted us to investigate the composition and effects of the Lavandula coronopifolia oil from Palestine on cancer cells and AMPA receptor subunits in the brain due to the vast range of beneficial properties of Lavandula coronopifolia essential oil (EO). GC/MS was used to analyze L. coronopifolia's EO chemistry.
View Article and Find Full Text PDFACS Chem Neurosci
December 2022
Department of Nuclear Medicine, Zhongshan Hospital, Fudan University, Shanghai 200032, China.
P2X7 receptors (P2X7R), as a brain inflammation biomarker, play important roles in the epileptogenic progress. Mounting evidence supports their activation in the brain during epilepsy, and inhibition of the P2X7 receptor reduces the seizure frequency and severity. In this study, we investigate P2X7R-targeted (F-FTTM) position emission tomography (PET) imaging in a rat model of temporal lobe epilepsy to obtain further insights into the role of P2X7R during epileptogenesis.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!